• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Stealth BioTherapeutics Corp. ADS (Amendment)

    9/23/22 5:20:21 PM ET
    $MITO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MITO alert in real time by email
    SC 13D/A 1 tm2226374d1_sc13da.htm SC 13D/A

     

    CUSIP No. 85788D100

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  

     

    SCHEDULE 13D/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 10)*

     

    Stealth BioTherapeutics Corp

    (Name of Issuer)

     

    Ordinary Shares, par value $0.0003 per share

    (Title of Class of Securities)

     

    85788D100

    (CUSIP Number)

     

    Gregg L. Katz

    Joshua M. Zachariah

    Sean M. Donahue

    Goodwin Procter LLP

    100 Northern Avenue
    Boston, MA 02210
    617.570.1000

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    September 23, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

     

     

    CUSIP No. 85788D100

     

    (1) Names of Reporting Persons
    Morningside Venture (I) Investments Limited
     
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
     
    (3) SEC Use Only
     
    (4) Source of Funds (See Instructions)
    WC
     
    (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
     
    (6) Citizenship or Place of Organization
    British Virgin Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    (7) Sole Voting Power
    0
     
    (8) Shared Voting Power
    740,265,268(1)(2)(3)
     
    (9) Sole Dispositive Power
    0
     
    (10) Shared Dispositive Power
    740,265,268(1)(2)(3)

     

    (11) Aggregate Amount Beneficially Owned by Each Reporting Person
    740,265,268(1)(2)(3)
     
    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
     
    (13) Percent of Class Represented by Amount in Row (11)
    66.8%(4)
     
    (14) Type of Reporting Person (See Instructions)
    CO

     

    (1) The Ordinary Shares (as defined below) beneficially owned may be exchanged into American Depositary Shares (“ADSs”) on a twelve-for-one basis.

     

    (2) Includes 514,672,111 Ordinary Shares, including Ordinary Shares represented by ADSs, held directly by MV(I)IL (as defined below).

     

    (3) Includes the right by MV(I)IL to acquire (i) 224,993,157 Ordinary Shares upon the exercise of warrants and (ii) 600,000 Ordinary Shares upon the exercise of an option to purchase Ordinary Shares.

     

    (4) Based on 882,582,802 Ordinary Shares outstanding as of May 31, 2022 as reported in the Issuer’s Form F-1 Registration Statement filed with the Securities and Exchange Commission (the “SEC”) on June 3, 2022.

     

     

     

     

    CUSIP No. 85788D100

     

    (1) Names of Reporting Persons
    Frances Anne Elizabeth Richard
       
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
     
    (3) SEC Use Only
     
    (4) Source of Funds (See Instructions)
    AF
     
    (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
     
    (6) Citizenship or Place of Organization
    United Kingdom

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    (7) Sole Voting Power
    0
     
    (8) Shared Voting Power
    741,652,468 (1)(2)(3)(4)
     
    (9) Sole Dispositive Power
    0
     
    (10) Shared Dispositive Power
    741,652,468 (1)(2)(3)(4)
     

    (11) Aggregate Amount Beneficially Owned by Each Reporting Person
    741,652,468 (1)(2)(3)(4)
     
    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
       
    (13) Percent of Class Represented by Amount in Row (11)
    66.9%(5)
     
    (14) Type of Reporting Person (See Instructions)
    IN

     

    (1) The Ordinary Shares (as defined below) beneficially owned may be exchanged into ADSs on a twelve-for-one basis.

     

    (2) Includes 514,672,111 Ordinary Shares, including Ordinary Shares represented by ADSs, held directly by MV(I)IL (as defined below). Ms. Richard shares voting and dispositive power with respect to the securities held by MV(I)IL as a result of her position as a director.

     

    (3) Includes the right by MV(I)IL to acquire (i) 224,993,157 Ordinary Shares upon the exercise of warrants and (ii) 600,000 Ordinary Shares upon the exercise of an option to purchase Ordinary Shares. Ms. Richard shares voting and dispositive power with respect to the securities held by MV(I)IL as a result of her position as a director.

     

    (4) Includes 1,387,200 Ordinary Shares representing 115,600 ADSs held directly by GCAL (as defined below). Ms. Richard shares voting and dispositive power with respect to the securities held by GCAL as a result of her position as a director.

     

    (5) Based on 882,582,802 Ordinary Shares outstanding as of May 31, 2022 as reported in the Issuer’s Form F-1 Registration Statement filed with the SEC on June 3, 2022.

     

     

     

     

    CUSIP No. 85788D100

     

    (1) Names of Reporting Persons
    Jill Marie Franklin
       
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
     
    (3) SEC Use Only
     
    (4) Source of Funds (See Instructions)
    AF
     
    (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
     
    (6) Citizenship or Place of Organization
    United Kingdom

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    (7) Sole Voting Power
    0
     
    (8) Shared Voting Power
    741,652,468 (1)(2)(3)(4)
     
    (9) Sole Dispositive Power
    0
     
    (10) Shared Dispositive Power
    741,652,468 (1)(2)(3)(4)
     

    (11) Aggregate Amount Beneficially Owned by Each Reporting Person
    741,652,468 (1)(2)(3)(4)
     
    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
     
    (13) Percent of Class Represented by Amount in Row (11)
    66.9%(5)
     
    (14) Type of Reporting Person (See Instructions)
    IN

     

    (1) The Ordinary Shares (as defined below) beneficially owned may be exchanged into ADSs on a twelve-for-one basis.

     

    (2) Includes 514,672,111 Ordinary Shares, including Ordinary Shares represented by ADSs, held directly by MV(I)IL (as defined below). Ms. Franklin shares voting and dispositive power with respect to the securities held by MV(I)IL as a result of her position as a director.

     

    (3) Includes the right by MV(I)IL to acquire (i) 224,993,157 Ordinary Shares upon the exercise of warrants and (ii) 600,000 Ordinary Shares upon the exercise of an option to purchase Ordinary Shares. Ms. Franklin shares voting and dispositive power with respect to the securities held by MV(I)IL as a result of her position as a director.

     

    (4) Includes 1,387,200 Ordinary Shares representing 115,600 ADSs held directly by GCAL (as defined below). Ms. Franklin shares voting and dispositive power with respect to the securities held by GCAL as a result of her position as a director.

     

    (5) Based on 882,582,802 Ordinary Shares outstanding as of May 31, 2022 as reported in the Issuer’s Form F-1 Registration Statement filed with the SEC on June 3, 2022.

     

     

     

     

    CUSIP No. 85788D100

     

    (1) Names of Reporting Persons
    Peter Stuart Allenby Edwards
       
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
     
    (3) SEC Use Only
     
    (4) Source of Funds (See Instructions)
    AF
     
    (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
     
    (6) Citizenship or Place of Organization
    United Kingdom

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    (7) Sole Voting Power
    0
     
    (8) Shared Voting Power
    740,265,268 (1)(2)(3)
     
    (9) Sole Dispositive Power
    0
     
    (10) Shared Dispositive Power
    740,265,268 (1)(2)(3)
     
    (11) Aggregate Amount Beneficially Owned by Each Reporting Person
    740,265,268 (1)(2)(3)
     
    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
     
    (13) Percent of Class Represented by Amount in Row (11)
    66.8%(4)
     
    (14) Type of Reporting Person (See Instructions)
    IN

      

    (1) The Ordinary Shares (as defined below) beneficially owned may be exchanged into ADSs on a twelve-for-one basis.

     

    (2) Includes 514,672,111 Ordinary Shares, including Ordinary Shares represented by ADSs, held directly by MV(I)IL (as defined below). Mr. Edwards shares voting and dispositive power with respect to the securities held by MV(I)IL as a result of his position as a director.

     

    (3) Includes the right by MV(I)IL to acquire (i) 224,993,157 Ordinary Shares upon the exercise of warrants and (ii) 600,000 Ordinary Shares upon the exercise of an option to purchase Ordinary Shares. Mr. Edwards shares voting and dispositive power with respect to the securities held by MV(I)IL as a result of his position as a director.

     

    (4) Based on 882,582,802 Ordinary Shares outstanding as of May 31, 2022 as reported in the Issuer’s Form F-1 Registration Statement filed with the SEC on June 3, 2022.

     

     

     

     

    CUSIP No. 85788D100 

     

    (1) Names of Reporting Persons
    Cheung Ka Ho
     
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨

     
    (3) SEC Use Only
     
    (4) Source of Funds (See Instructions)
    AF
     
    (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
     
    (6) Citizenship or Place of Organization
    Hong Kong

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    (7) Sole Voting Power
    0
     
    (8) Shared Voting Power
    740,265,268 (1)(2)(3)
     
    (9) Sole Dispositive Power
    0
     
    (10) Shared Dispositive Power
    740,265,268 (1)(2)(3)

     
    (11) Aggregate Amount Beneficially Owned by Each Reporting Person
    740,265,268 (1)(2)(3)
     
    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
     
    (13) Percent of Class Represented by Amount in Row (11)
    66.8%(4)
     
    (14) Type of Reporting Person (See Instructions)
    IN

     

    (1) The Ordinary Shares (as defined below) beneficially owned may be exchanged into ADSs on a twelve-for-one basis.

     

    (2) Includes 514,672,111 Ordinary Shares, including Ordinary Shares represented by ADSs, held directly by MV(I)IL (as defined below). Mr. Cheung shares voting and dispositive power with respect to the securities held by MV(I)IL as a result of his position as a director.

     

    (3) Includes the right by MV(I)IL to acquire (i) 224,993,157 Ordinary Shares upon the exercise of warrants and (ii) 600,000 Ordinary Shares upon the exercise of an option to purchase Ordinary Shares. Mr. Cheung shares voting and dispositive power with respect to the securities held MV(I)IL as a result of his position as a director.

     

    (4) Based on 882,582,802 Ordinary Shares outstanding as of May 31, 2022 as reported in the Issuer’s Form F-1 Registration Statement filed with the SEC on June 3, 2022.

     

     

     

     

    CUSIP No. 85788D100

     

    (1) Names of Reporting Persons
    Equal Talent Investments Limited
     
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
     
    (3) SEC Use Only
     
    (4) Source of Funds (See Instructions)
    WC
     
    (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
     
    (6) Citizenship or Place of Organization
    British Virgin Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    (7) Sole Voting Power
    19,533,720 (1)(2)
     
    (8) Shared Voting Power
    0
     
    (9) Sole Dispositive Power
    19,533,720 (1)(2)
     
    (10) Shared Dispositive Power
    0
     

    (11) Aggregate Amount Beneficially Owned by Each Reporting Person
    19,533,720 (1)(2)
     
    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
     
    (13) Percent of Class Represented by Amount in Row (11)
    2.2%(3)
     
    (14) Type of Reporting Person (See Instructions)
    CO 

     

    (1) The Ordinary Shares (as defined below) beneficially owned may be exchanged into ADSs on a twelve-for-one basis.

     

    (2) Represents 19,533,720 Ordinary Shares representing 1,627,810 ADSs held directly by ETIL (as defined below).

     

    (3) Based on 882,582,802 Ordinary Shares outstanding as of May 31, 2022 as reported in the Issuer’s Form F-1 Registration Statement filed with the SEC on June 3, 2022.

     

     

     

     

    CUSIP No. 85788D100

     

    (1) Names of Reporting Persons
    Season Pioneer Investments Limited
     
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
     

    (3) SEC Use Only
     
    (4) Source of Funds (See Instructions)
    WC
     
    (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
     
    (6) Citizenship or Place of Organization
    British Virgin Islands
     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    (7) Sole Voting Power
    39,066,276 (1)(2)
     
    (8) Shared Voting Power
    0
     
    (9) Sole Dispositive Power
    39,066,276 (1)(2)
     
    (10) Shared Dispositive Power
    0

     

    (11) Aggregate Amount Beneficially Owned by Each Reporting Person
    39,066,276 (1)(2)
     
    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
     
    (13) Percent of Class Represented by Amount in Row (11)
    4.4%(3)
     
    (14) Type of Reporting Person (See Instructions)
    CO

     

    (1) The Ordinary Shares (as defined below) beneficially owned may be exchanged into ADSs on a twelve-for-one basis.

     

    (2) Represents 39,066,276 Ordinary Shares representing 3,255,523 ADSs held directly by SPIL (as defined below).

     

    (3) Based on 882,582,802 Ordinary Shares outstanding as of May 31, 2022 as reported in the Issuer’s Form F-1 Registration Statement filed with the SEC on June 3, 2022.

     

     

     

     

    CUSIP No. 85788D100

     

    (1) Names of Reporting Persons
    Suk Ying Pauli Ng
       
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
     
    (3) SEC Use Only
     
    (4) Source of Funds (See Instructions)
    AF
     
    (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
     
    (6) Citizenship or Place of Organization
    Hong Kong
     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    (7) Sole Voting Power
    58,599,996 (1)(2)(3)
     
    (8) Shared Voting Power
     0
     
    (9) Sole Dispositive Power
    58,599,996 (1)(2)(3)
     
    (10) Shared Dispositive Power
     0

     

    (11) Aggregate Amount Beneficially Owned by Each Reporting Person
    58,599,996 (1)(2)(3)
     
    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
     
    (13) Percent of Class Represented by Amount in Row (11)
    6.6%(4)
       
    (14) Type of Reporting Person (See Instructions)
    IN

     

    (1) The Ordinary Shares (as defined below) beneficially owned may be exchanged into ADSs on a twelve-for-one basis.

     

    (2) Includes 19,533,720 Ordinary Shares representing 1,627,810 ADSs held directly by ETIL (as defined below). Ms. Ng has sole voting and dispositive power with respect to the securities held by ETIL as a result of her position as a director.

     

    (3) Includes 39,066,276 Ordinary Shares representing 3,255,523 ADSs held directly by SPIL (as defined below). Ms. Ng has sole voting and dispositive power with respect to the securities held by SPIL as a result of her position as a director.

     

    (4) Based on 882,582,802 Ordinary Shares outstanding as of May 31, 2022 as reported in the Issuer’s Form F-1 Registration Statement filed with the SEC on June 3, 2022.

     

     

     

     

    CUSIP No. 85788D100

     

    (1) Names of Reporting Persons
    Golwyn Capital Appreciation Limited
       
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
     
    (3) SEC Use Only
     
    (4) Source of Funds (See Instructions)
    WC

     

    (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
     
    (6) Citizenship or Place of Organization
    British Virgin Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    (7) Sole Voting Power
    0
     
    (8) Shared Voting Power
    1,387,200 (1)(2)
     
    (9) Sole Dispositive Power
    0
     
    (10) Shared Dispositive Power
    1,387,200 (1)(2)

     

    (11) Aggregate Amount Beneficially Owned by Each Reporting Person
    1,387,200 (1)(2)
     
    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
     
    (13) Percent of Class Represented by Amount in Row (11)
    0.2%(3)
       
    (14) Type of Reporting Person (See Instructions)
    CO

     

    (1) The Ordinary Shares (as defined below) beneficially owned may be exchanged into ADSs on a twelve-for-one basis.

     

    (2) Represents 1,387,200 Ordinary Shares representing 115,600 ADSs held directly by GCAL (as defined below).

     

    (3) Based on 882,582,802 Ordinary Shares outstanding as of May 31, 2022 as reported in the Issuer’s Form F-1 Registration Statement filed with the SEC on June 3, 2022.

     

     

     

     

    CUSIP No. 85788D100

     

    Item 1. Security and Issuer.

     

    This Amendment No. 10 (“Amendment No. 10”) amends the Schedule 13D filed with the SEC on February 28, 2019 (the “Original Schedule 13D”), which Original Schedule 13D was amended by Amendment No. 1 to the Original Schedule 13D filed on March 22, 2019 (“Amendment No. 1”), Amendment No. 2 to the Original Schedule 13D filed on May 24, 2019 (“Amendment No. 2”), Amendment No. 3 to the Original Schedule 13D filed on April 16, 2020 (“Amendment No. 3”), Amendment No. 4 to the Original Schedule 13D filed on November 9, 2020 (“Amendment No. 4”), Amendment No. 5 to the Original Schedule 13D filed on February 17, 2021 (“Amendment No. 5), Amendment No. 6 to the Original Schedule 13D filed on November 22, 2021 (“Amendment No. 6”), Amendment No. 7 to the Original Schedule 13D filed on December 10, 2021 (“Amendment No. 7”), Amendment No. 8 to the Original Schedule 13D filed on June 27, 2022 (“Amendment No. 8”) and Amendment No. 9 to the Original Schedule 13D filed on August 1, 2022 (“Amendment No. 9”) and together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment No. 8 and Amendment No. 9 (the “Amended Schedule 13D”), and relates to the Reporting Persons’ (as defined in Item 2 below) beneficial ownership of the ordinary shares, par value $0.0003 per share (the “Ordinary Shares”), of Stealth BioTherapeutics Corp, a Cayman Islands company (the “Issuer”), which conducts its operations in the United States through Stealth BioTherapeutics, Inc., a Delaware corporation (“Stealth Delaware”). The address of the principal executive office of Stealth Delaware is 140 Kendrick Street, Needham, MA 02494. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    Except as otherwise described herein, the information contained in the Amended Schedule 13D remains in effect. Capitalized terms used but not defined in this Amendment No. 10 shall have the respective meanings set forth with respect thereto in the Amended Schedule 13D.

     

    Item 2. Identity and Background.

     

    No changes, except as set forth below.

     

    (a) This statement is filed by:

     

      (i) Morningside Venture (I) Investments Limited, a British Virgin Islands exempted company (“MV(I)IL”), with respect to the Ordinary Shares directly and beneficially owned by it;
      (ii) Frances Anne Elizabeth Richard, with respect to the Ordinary Shares beneficially owned by her as a result of her position as a director with MV(I)IL and as a director with Golwyn Capital Appreciation Limited, a British Virgin Islands exempted company (“GCAL”);
      (iii) Jill Marie Franklin, with respect to the Ordinary Shares beneficially owned by her as a result of her position as a director with MV(I)IL and as a director with GCAL;
      (iv) Peter Stuart Allenby Edwards, with respect to the Ordinary Shares beneficially owned by him as a result of his position as a director with MV(I)IL;
      (v) Cheung Ka Ho, with respect to the Ordinary Shares beneficially owned by him as a result of his position as a director with MV(I)IL;
      (vi) Equal Talent Investments Limited, a British Virgin Islands exempted company (“ETIL”), with respect to the Ordinary Shares beneficially owned by it;
      (vii) Season Pioneer Investments Limited, a British Virgin Islands exempted company (“SPIL”), with respect to the Ordinary Shares beneficially owned by it;
      (viii) Suk Ying Pauli Ng, with respect to the Ordinary Shares beneficially owned by her as a result of her positions as a director with ETIL and as a director with SPIL; and
      (ix) GCAL, with respect to the Ordinary Shares directly and beneficially owned by it.

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

     

     

     

    Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of MV(I)IL and share voting and dispositive power with respect to the securities held by MV(I)IL. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned directly by MV(I)IL. MV(I)IL disclaims beneficial ownership of the securities owned directly by ETIL, SPIL and GCAL. MV(I)IL is ultimately wholly beneficially owned by a trust over which Madam Chan Tan Ching Fen has sole authority to remove the trustee.

     

    Suk Ying Pauli Ng is the sole director of ETIL and has sole voting and dispositive power with respect to the securities held by ETIL. Ms. Ng disclaims beneficial ownership of the securities owned directly by ETIL. ETIL disclaims beneficial ownership of the securities owned directly by MV(I)IL, SPIL and GCAL. ETIL is ultimately wholly beneficially owned by a trust over which Peter Stuart Allenby Edwards has sole authority to remove the trustee.

     

    Suk Ying Pauli Ng is the sole director of SPIL and has sole voting and dispositive power with respect to the securities held by SPIL. Ms. Ng disclaims beneficial ownership of the securities owned directly by SPIL. SPIL disclaims beneficial ownership of the securities owned directly by MV(I)IL, ETIL and GCAL. SPIL is ultimately wholly beneficially owned by a trust over which Peter Stuart Allenby Edwards has sole authority to remove the trustee.

     

    Frances Anne Elizabeth Richard and Jill Marie Franklin are the directors of GCAL and share voting and dispositive power with respect to the securities held by GCAL. Ms. Richard and Ms. Franklin each disclaim beneficial ownership of the securities owned directly by GCAL. GCAL disclaims beneficial ownership of the securities owned directly by MV(I)IL, ETIL and SPIL. GCAL is ultimately wholly beneficially owned by a trust over which Chan Suet Ying and Adriel Chan share authority to remove the trustee.

     

    (b) The business address of each of the Reporting Persons is:

     

    (i) With respect to MV(I)IL, Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung:

    c/o THC Management Services S.A.M.,

    2nd Floor, Le Prince De Galles

    3-5 Avenue Des Citronniers 

    MC 98000, Monaco 

    With copies to: 

    Morningside Technology Advisory, LLC 

    Attn: Stephanie O’Brien, Esq. 

    1188 Centre Street 

    Newton Centre, MA 02459 

    Springfield Financial Advisory Limited 

    Attn: Investment Administration Department 

    22nd Floor Hang Lung Centre 

    2-20 Paterson Street 

    Causeway Bay, Hong Kong

     

    (ii) With respect to ETIL and Ms. Ng: 

    c/o THC Management Services S.A.M., 

    2nd Floor, Le Prince De Galles 

    3-5 Avenue Des Citronniers 

    MC 98000, Monaco 

    With copies to: 

    Morningside Technology Advisory, LLC 

    Attn: Stephanie O’Brien, Esq. 

    1188 Centre Street 

    Newton Centre, MA 02459 

    Springfield Financial Advisory Limited 

    Attn: Investment Administration Department 

    22nd Floor Hang Lung Centre 

    2-20 Paterson Street 

    Causeway Bay, Hong Kong

     

     

     

     

    (iii) With respect to SPIL and Ms. Ng:

     

    c/o THC Management Services S.A.M., 

    2nd Floor, Le Prince De Galles 

    3-5 Avenue Des Citronniers 

    MC 98000, Monaco 

    With copies to: 

    Morningside Technology Advisory, LLC 

    Attn: Stephanie O’Brien, Esq. 

    1188 Centre Street 

    Newton Centre, MA 02459 

    Springfield Financial Advisory Limited 

    Attn: Investment Administration Department 

    22nd Floor Hang Lung Centre 

    2-20 Paterson Street 

    Causeway Bay, Hong Kong

     

    (iv) With respect to GCAL, Ms. Richard and Ms. Franklin:

     

    c/o THC Management Services S.A.M., 

    2nd Floor, Le Prince De Galles 

    3-5 Avenue Des Citronniers 

    MC 98000, Monaco 

    With copies to: 

    Morningside Technology Advisory, LLC 

    Attn: Stephanie O’Brien, Esq. 

    1188 Centre Street 

    Newton Centre, MA 02459 

    Springfield Financial Advisory Limited 

    Attn: Investment Administration Department

    22nd Floor Hang Lung Centre 

    2-20 Paterson Street 

    Causeway Bay, Hong Kong

     

    (c) The present principal business of MV(I)IL, Ms. Richard, Ms. Franklin, Mr. Edwards, Mr. Cheung, ETIL, SPIL, Ms. Ng and GCAL is the venture capital and private equity investment business.

     

    (d) No Reporting Person, during the last five years, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) No Reporting Person, during the last five years, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) Citizenship of the Reporting Persons is as set forth below:

     

    MV(I)IL British Virgin Islands
    Ms. Richard United Kingdom
    Ms. Franklin United Kingdom
    Mr. Edwards United Kingdom
    Mr. Cheung Hong Kong
    ETIL British Virgin Islands
    SPIL British Virgin Islands
    Ms. Ng Hong Kong
    GCAL British Virgin Islands

     

     

     

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    No changes.

     

    Item 4. Purpose of Transaction.

     

    No changes.

     

    Item 5. Interest in Securities of the Issuer.

     

    No changes.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    No changes.

     

    Item 7. Material to be Filed as Exhibits.

     

    No changes, except as set forth below.

     

    The following documents are filed as Exhibits to this statement:

     

    Exhibit
    Number
      Exhibit Description
    99.1   Joint Filing Agreement (filed herewith)
    99.2   Agreement and Plan of Merger, dated as of July 31, 2022, among Stealth Biotherapeutics Corp., Stealth Parent Limited, and Stealth Merger Sub Limited (incorporated by reference from a Form 6-K filed by the Issuer on August 1, 2022)
    99.3   Limited Guarantee, dated as of July 31, 2022, by and between Stealth Biotherapeutics Corp. and Morningside Venture (I) Investments Limited (incorporated by reference from a Form 6-K filed by the Issuer on August 1, 2022)
    99.4   Limited Guarantee, dated as of July 31, 2022, by and between Stealth Biotherapeutics Corp. and J. Wood Capital Advisors LLC (incorporated by reference from a Form 6-K filed by the Issuer on August 1, 2022)
    99.5   Voting and Support Agreement, dated as of July 31, 2022, by and between Stealth Biotherapeutics Corp. and certain shareholders listed on Schedule A thereto (incorporated by reference from a Form 6-K filed by the Issuer on August 1, 2022)
    99.6   Interim Investors Agreement, dated as of July 31, 2022, by and between Morningside Venture (I) Investments Limited and J. Wood Capital Advisors LLC (incorporated by reference from Amendment No. 9 to the Original Schedule 13D filed on August 1, 2022).
    99.7   Ordinary Share Purchase Agreement dated as of April 10, 2022 by and between Stealth BioTherapeutics Corp and Morningside Venture (I) Investments Limited (incorporated by reference from a Form 6-K filed by the Issuer on April 11, 2022)
    99.8   Form of Morningside Warrant (incorporated by reference from a Form 6-K filed by the Issuer on April 11, 2022)
    99.9   Proposal dated June 24, 2022 (incorporated by reference from a Form 6-K filed by the Issuer on June 27, 2022).

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Agreement listed on Exhibit 99.1 hereto.

     

    Dated: September 23, 2022

     

    For and on behalf of

    MORNINGSIDE VENTURE (I) INVESTMENTS LIMITED  
       
    By: /s/ Frances Anne Elizabeth Richard  
      Frances Anne Elizabeth Richard, Director  
         
    /s/ Frances Anne Elizabeth Richard  
    Frances Anne Elizabeth Richard  
       
    /s/ Jill Marie Franklin  
    Jill Marie Franklin  
       
    /s/ Peter Stuart Allenby Edwards  
    Peter Stuart Allenby Edwards  
       
    /s/ Cheung Ka Ho  
    Cheung Ka Ho  
       
    For and on behalf of  
    EQUAL TALENT INVESTMENTS LIMITED  
       
    By: /s/ Suk Ying Pauli Ng  
      Suk Ying Pauli Ng, Director  
         
    /s/ Suk Ying Pauli Ng  
    Suk Ying Pauli Ng  
       
    For and on behalf of  
    SEASON PIONEER INVESTMENTS LIMITED  
       
    By: /s/ Suk Ying Pauli Ng  
      Suk Ying Pauli Ng, Director  
         
    /s/ Suk Ying Pauli Ng  
    Suk Ying Pauli Ng  
       
    For and on behalf of  
    GOLWYN CAPITAL APPRECIATION LIMITED  
       
    By: /s/ Frances Anne Elizabeth Richard  
      Frances Anne Elizabeth Richard, Director  
         
    /s/ Jill Marie Franklin  
    Jill Marie Franklin  

     

     

    Get the next $MITO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MITO

    DatePrice TargetRatingAnalyst
    7/1/2021$3.00Buy
    Maxim Group
    More analyst ratings

    $MITO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stealth BioTherapeutics Corp Announces Completion of Merger

      BOSTON, Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the completion of the merger (the "Merger") with Stealth Merger Sub Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands ("Merger Sub"), pursuant to the previously announced Agreement and Plan of Merger, dated as of July 31, 2022 (the "Merger Agreement"), among the Company, Stealth Parent Limited, an exempted company with limited liabilit

      11/16/22 4:01:00 PM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

      SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model SBT-272 Granted Orphan Drug Designation for Treatment of ALS BOSTON, Nov. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced encouraging Phase 1 data on the safety and tolerability of SBT-272, a next-generation small molecule designed to reach therapeutic concentrations in the brain and to restore mitochondrial structure and functi

      11/1/22 7:30:00 AM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders

      BOSTON, Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that it has called an extraordinary general meeting of shareholders (the  "EGM"), to be held at 9:30 a.m. (New York City time) on November 15, 2022, at Foley & Lardner LLP, 111 Huntington Ave Suite 2600, Boston, MA 02199, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of July 31, 2022 (the "Merger Agreem

      10/7/22 4:01:00 PM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MITO
    Financials

    Live finance-specific insights

    See more
    • STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY

      Study did not meet primary endpoints of mean change in low luminance visual acuity (LLVA) and geographic atrophy (GA) progression Categorical improvement in LLVA, with >15% of elamipretide-treated patients gaining 2+ lines of vision at Week 48 Elamipretide demonstrated enhanced ellipsoid zone preservation through reduction of progressive attenuation, an important indicator of photoreceptor loss. Company to host conference call and webcast today at 8:30 a.m. ET BOSTON, May 2, 2022 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysf

      5/2/22 7:30:00 AM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

      BOSTON, Nov. 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the three months ended September 30, 2021 and announced recent business highlights. "We are excited to broaden our clinical development efforts with multiple new trial initiations expected over the coming months," said Reenie McCarthy, Chief Executive Officer at Stealth. "We are highly enthusia

      11/11/21 7:30:00 AM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11

      BOSTON, Nov. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report third quarter 2021 financial results on Thursday, November 11, before the market opens. Management will host a conference call at 8:30 am ET that day to discuss the financial results and provide a general business update. The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0

      11/4/21 7:30:00 AM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MITO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Stealth BioTherapeutics Corp. ADS

      15-12G - Stealth BioTherapeutics Corp (0001696396) (Filer)

      11/28/22 4:30:29 PM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Stealth BioTherapeutics Corp. ADS

      EFFECT - Stealth BioTherapeutics Corp (0001696396) (Filer)

      11/18/22 12:15:15 AM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Stealth BioTherapeutics Corp. ADS

      EFFECT - Stealth BioTherapeutics Corp (0001696396) (Filer)

      11/18/22 12:15:24 AM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MITO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Stealth BioTherapeutics with a new price target

      Maxim Group initiated coverage of Stealth BioTherapeutics with a rating of Buy and set a new price target of $3.00

      7/1/21 8:34:40 AM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MITO
    Leadership Updates

    Live Leadership Updates

    See more
    • Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board

      Cognito Therapeutics, a Phase 3-ready disease-modifying digital therapeutics company, today announced the appointment of Gerald Chan, ScD. as Chairman of the Board. Cognito is a pioneer in using neuromodulation to engage novel targets of neuronal pathophysiology to achieve disease modification in neurodegenerative diseases. Dr. Chan is the co-founder of Morningside, a privately held venture capital and private equity firm. Since inception, Morningside has focused on the development and commercialization of novel scientific discoveries in both the life sciences and technology sectors. "The use of non-pharmacological interventions to treat neurocognitive decline represents a fundamental shif

      7/6/21 8:00:00 AM ET
      $MITO
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MITO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Stealth BioTherapeutics Corp. ADS (Amendment)

      SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)

      9/23/22 5:20:21 PM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Stealth BioTherapeutics Corp. ADS (Amendment)

      SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)

      8/1/22 4:46:01 PM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Stealth BioTherapeutics Corp. ADS (Amendment)

      SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)

      6/27/22 4:49:16 PM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care